GoodRx Holdings, Inc. (NASDAQ:GDRX) is a company that provides consumers with information and tools to save on prescription drugs. It operates a platform that aggregates pricing data from pharmacies across the United States, helping users find the best prices for their medications. GoodRx competes with other companies in the healthcare and technology sectors, such as Amazon Pharmacy and Blink Health.
On August 11, 2025, George Hill from Deutsche Bank set a price target of $6 for GoodRx. At that time, the stock was trading at $3.47, suggesting a potential price increase of approximately 72.91%. This optimistic outlook comes shortly after GoodRx's Q2 2025 earnings call, which took place on August 7, 2025. The call featured key company figures, including CEO Wendy Barnes and CFO Christopher A. McGinnis, who discussed the company's financial performance and future strategies.
During the earnings call, GoodRx's stock was trading at $3.47, with a daily low of $3.40 and a high of $3.55. Over the past year, the stock has seen a high of $8.80 and a low of $3.30. The company's market capitalization is approximately $1.22 billion, and it has a trading volume of 3,260,336 shares. These figures highlight the stock's volatility and the potential for significant price movement.
The earnings call also included participation from Charles Rhyee of TD Cowen, Research Division, and Daniel R. Their involvement indicates a strong interest from the investment community in GoodRx's performance and strategic direction. As the company continues to navigate the competitive landscape, investors will be closely monitoring its progress and any developments that could impact its stock price.
